What is claimed is:

1. A method of inhibiting TACI activity, BCMA activity, or both in a mammal, which comprises administering a specific binding partner for APRIL, wherein the specific binding partner comprises
    a. the consensus region of TACI (SEQ ID NO: 16);
    b. the consensus region of BCMA (SEQ ID NO: 7);
    c. the TACI/BCMA extracellular consensus sequence (SEQ ID NO: 13);

    but does not comprise the extracellular region of TACI (SEQ ID NO: 15) or the extracellular region of BCMA (SEQ ID NO: 6).
2. The method of Claim 1, further comprising administering a specific binding partner for AGP-3.
3. A method of treating B-cell lymphoproliferative disorders, which comprises administering a therapeutic agent comprising a specific binding partner selected from:
    a. the consensus region of TACI (SEQ ID NO: 16);
    b. the consensus region of BCMA (SEQ ID NO: 7); or
    c. the TACI/BCMA extracellular consensus sequence (SEQ ID NO: 13)

    but not comprising the extracellular region of TACI (SEQ ID NO: 15) or the extracellular region of BCMA (SEQ ID NO: 6)..
4. A method of treating T-cell lymphoproliferative disorders, which comprises administering a therapeutic agent comprising a specific binding partner selected from selected from:
    a. the consensus region of TACI (SEQ ID NO: 16);
    b. the consensus region of BCMA (SEQ ID NO: 7); or
    c. the TACI/BCMA extracellular consensus sequence (SEQ ID NO: 13)

but not comprising the extracellular region of TACI (SEQ ID NO: 15) or the extracellular region of BCMA (SEQ ID NO: 6)..

5. A method of treating one or more solid tumors, which comprises administering a therapeutic agent comprising a specific binding partner selected from:

    a. the consensus region of TACI (SEQ ID NO: 16);
    b. the consensus region of BCMA (SEQ ID NO: 7); or
    c. the TACI/BCMA extracellular consensus sequence (SEQ ID NO: 13)

but not comprising the extracellular region of TACI (SEQ ID NO: 15) or the extracellular region of BCMA (SEQ ID NO: 6).

6. The method of Claim 5, wherein the tumor is selected from lung, gastrointestinal, pancreatic and prostate

7. The method of any of Claims 1, 3, 4, or 5, wherein the specific binding partner is comprised within a molecule of the formula

$$(X^1)_a\text{-}F^1\text{-}(X^2)_b$$

wherein:

F^1 is a vehicle;

X^1 and X^2 are each independently selected from $\text{-}(L^1)_c\text{-}P^1$, $\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$, $\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3$, and $\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3\text{-}(L^4)_f\text{-}P^4$

at least one of P^1, P^2, P^3, and P^4 is the ;

L^1, L^2, L^3, and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1.

8. The method of Claim 7, wherein the molecule comprises a structure of the formulae

$$X^1\text{-}F^1$$

or

$$F^1\text{-}X^2.$$

9. The method of Claim 7, wherein the molecule comprises a structure of the formula

$$F^1\text{-}(L^1)_c\text{-}P^1.$$

10. The method of Claim 7, wherein the molecule comprises a structure of the formula

$$F^1\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$$

wherein one of P^1 and P^2 is the consensus region of TACI (SEQ ID NO: 16) and the other is the consensus region for BCMA (SEQ ID NO: 7).

11. The method of Claim 10, wherein the vehicle is an Fc domain.

12. The method of any of Claims 1, 3, 4, or 5, wherein the specific binding partner replaces a CDR region within an antibody molecule.

13. A composition of matter of the formula

$$(X^1)_a\text{-}F^1\text{-}(X^2)_b$$

wherein:

F^1 is a vehicle;

X^1 and X^2 are each independently selected from $-(L^1)_c\text{-}P^1$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3$, and $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3\text{-}(L^4)_f\text{-}P^4$

P^1, P^2, P^3, and P^4 are each independently

a. the consensus region of TACI (SEQ ID NO: 16);

b. the consensus region of BCMA (SEQ ID NO: 7); or

c. the TACI/BCMA extracellular consensus sequence (SEQ ID NO: 13),

but not the extracellular region of TACI (SEQ ID NO: 15) or the extracellular region of BCMA (SEQ ID NO: 6)..; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1.

14. The composition of matter of Claim 13 of the formulae

$$X^1\text{-}F^1$$

or

$$F^1\text{-}X^2.$$

15. The composition of matter of Claim 14 of the formula

$$F^1\text{-}(L^1)_c\text{-}P^1.$$

16. The composition of matter of Claim 14 of the formula

$$F^1\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$$

wherein one of P^1 and P^2 is a specific binding partner for TACI and the other is a specific binding partner for BCMA.

17. The composition of matter of Claim 16, wherein the vehicle is an Fc domain.